Immutep Limited American Depositary Shares - IMMP STOCK NEWS

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the grant of patent no. 7030750 by the Japanese Patent Office for antibody molecules targeting LAG-3, crucial for cancer treatment. This divisional patent follows a previous grant in 2019, with corresponding patents in territories like Australia, China, Europe, and the U.S. The patent, co-owned with Novartis AG, will expire on March 13, 2035. LAG525, a humanized form of IMP701, is being evaluated by Novartis in clinical trials for cancer, with Immutep set to receive milestone payments and royalties upon commercialization.

Immutep Limited (NASDAQ: IMMP) announced that it received positive feedback from the FDA regarding its lead product, eftilagimod alpha (efti), for the treatment of metastatic breast cancer (MBC). The FDA supports advancing efti into a new registrational trial, AIPAC-003, which will optimize patient selection based on completed phase IIb AIPAC trial data. This follows earlier feedback from the EMA. The upcoming trial aims to solidify the best design for efti, which targets patients who are unlikely to benefit from conventional therapies.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced its participation in notable investor conferences, including the 42nd Annual Cowen Health Care Conference from March 7-9, 2022, where CEO Marc Voigt will present on March 8 at 9:10 am EST. A live webcast will be available. Additionally, Immutep will engage in a fireside chat at the Maxim Growth Conference from March 28-30, 2022, set for March 28 at 11:00 am EDT. Immutep focuses on developing LAG-3 related immunotherapies for cancer and autoimmune diseases.

Immutep (ASX: IMM; NASDAQ: IMMP) will present new data from its phase II TACTI-002 trial at the European Lung Cancer Congress (ELCC) 2022 in Prague and virtually from March 30 to April 2, 2022. The study evaluates eftilagimod alpha combined with KEYTRUDA® in patients with PD-L1 unselected, refractory metastatic non-small cell lung cancer (NSCLC). The poster presentation is scheduled for April 1, 2022, at 12:00 noon CEST by Dr. Matthew G. Krebs. Immutep aims to advance its LAG-3 related immunotherapeutic developments.

Immutep Limited (NASDAQ: IMMP) announced the grant of a new patent by the Australian Patent Office for its lead immunotherapy candidate, eftilagimod alpha (efti or IMP321). This patent, protecting combined preparations for treating cancer, follows similar grants in Europe, the U.S., and China. The claims cover specific combinations of efti with various anti-PD-1/PD-L1 antibodies, expiring on January 8, 2036. CEO Marc Voigt highlighted the importance of this patent in the context of significant interest in the LAG-3 mechanism following Phase III clinical data publication.

Immutep (ASX: IMM; NASDAQ: IMMP) has announced participation in two key investor conferences in February 2022. CEO Marc Voigt will present at the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, followed by a Q&A session on February 18 at 3:40 PM ET. Additionally, Immutep will be at the 2022 BIO CEO & Investor Conference from February 14-17. The company's focus is on developing immunotherapy treatments for cancer and autoimmune diseases, primarily through its lead candidate, eftilagimod alpha.

Immutep Limited (NASDAQ: IMMP) reported significant advancements in its clinical trials for cancer therapies, particularly its lead product, eftilagimod alpha (efti). The Phase IIb AIPAC trial demonstrated a notable overall survival benefit, with a +7.5 month increase for patients under 65 and +19.6 months for those with low monocytes. The company is preparing for a Phase III trial and has initiated patient recruitment for TACTI-003. Financially, cash on hand is $99.66 million, projected to fund operations until December 2023.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced a Manufacturing Service Agreement with Northway Biotech to produce its preclinical candidate, IMP761, aimed at autoimmune diseases. Northway will develop a GMP-compliant manufacturing process for IMP761 at its facility in Lithuania, with plans for clinical trials post-preclinical development. IMP761 targets autoimmune memory T cells expressing LAG-3, potentially addressing the root causes of autoimmune diseases. Preclinical results from 2019 indicated its ability to reduce T cell infiltration.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the treatment of the first five patients in its INSIGHT-003 study, which evaluates a triple combination therapy featuring eftilagimod alpha (efti) alongside chemotherapy and anti-PD-1 therapy. The study, led by Prof. Dr. Salah-Eddin Al-Batran, has reported no new safety signals and is progressing well, with patient recruitment on track. Up to 20 patients with solid tumors will be recruited, assessing safety, tolerability, and initial efficacy, with further results anticipated in 2022.